Published in PLoS One on August 28, 2009
Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol (2010) 1.28
Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ (2012) 1.21
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One (2014) 1.06
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol (2010) 0.90
Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings? BMJ Open (2016) 0.75
Early detection of HIV infection among Kenyan infants using a reverse transcriptase activity assay. Pediatr Infect Dis J (2012) 0.75
Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients. J Clin Microbiol (2017) 0.75
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med (2005) 8.13
Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet (2006) 5.34
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis (2006) 4.47
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr (2005) 2.75
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol (1999) 1.92
The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS (2007) 1.89
Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis (2007) 1.83
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS (2007) 1.77
Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol (2000) 1.64
HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg (2008) 1.48
Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr (2007) 1.32
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol (2005) 1.27
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res (2005) 1.15
Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol (2005) 1.14
Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes. Eur J Clin Microbiol Infect Dis (1999) 1.09
Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods (2007) 1.07
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 0.98
Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. J Virol Methods (2009) 0.96
Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis (2004) 4.73
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
United States anesthesiologists over 50: retirement decision making and workforce implications. Anesthesiology (2012) 2.61
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
Differences in clinical presentation among persons with pulmonary tuberculosis: a comparison of documented and undocumented foreign-born versus US-born persons. Clin Infect Dis (2008) 2.00
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
HIV testing for children in resource-limited settings: what are we waiting for? PLoS Med (2010) 1.87
Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis (2012) 1.82
S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet (2003) 1.74
Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis (2007) 1.59
Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis (2010) 1.52
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis (2009) 1.46
Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect (2011) 1.43
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics (2007) 1.39
Evolution and current use of the tuberculin test. Clin Infect Dis (2001) 1.34
Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis (2012) 1.33
Mutations in agr do not persist in natural populations of methicillin-resistant Staphylococcus aureus. J Infect Dis (2010) 1.27
Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis (2008) 1.22
Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol (2005) 1.14
Mycobacterium tuberculosis malate synthase- and MPT51-based serodiagnostic assay as an adjunct to rapid identification of pulmonary tuberculosis. Clin Vaccine Immunol (2006) 1.05
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther (2003) 1.02
Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis (2006) 1.01
Risk factors associated with postcraniotomy meningitis. Neurosurgery (2007) 1.01
Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res (2014) 0.93
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr (2004) 0.93
The Development and Implementation of an Outreach Program to Identify Acute and Recent HIV Infections in New York City. Open AIDS J (2010) 0.92
Correlation between HIV-Specific CD8 cell production of interferon- gamma and plasma levels of HIV RNA in perinatally infected pediatric populations. J Infect Dis (2004) 0.92
Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg (2010) 0.91
S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin Infect Dis (2008) 0.90
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med (2013) 0.89
Nasal carriage as a source of agr-defective Staphylococcus aureus bacteremia. J Infect Dis (2012) 0.89
Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS (2012) 0.89
Determinants of HIV drug resistance and public health implications in low- and middle-income countries. Antivir Ther (2012) 0.88
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses (2004) 0.88
Awake caudal anesthesia for inguinal surgery in one conjoined twin. Anesth Analg (2003) 0.85
Iatrogenic hyperthermia during cardiac magnetic resonance imaging. Anesth Analg (2004) 0.84
A reverse transcriptase assay for early diagnosis of infant HIV infection in resource-limited settings. J Trop Pediatr (2007) 0.84
Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia. J Urban Health (2005) 0.84
Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis (2002) 0.83
Acupuncture management of pain and emergence agitation in children after bilateral myringotomy and tympanostomy tube insertion. Paediatr Anaesth (2009) 0.82
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries. J Acquir Immune Defic Syndr (2011) 0.79
Obesity prevention in young schoolchildren: results of a pilot study. J Sch Health (2012) 0.79
Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis (2011) 0.78
Bioterrorism and children: unique concerns with infection control and vaccination. Anesthesiol Clin North America (2004) 0.76
Measurement of antiretroviral drugs in the lungs of HIV-infected patients. HIV Ther (2010) 0.76
Modeling the Impact of Retention Interventions on Mother-to-Child Transmission of HIV: Results From INSPIRE Studies in Malawi, Nigeria, and Zimbabwe. J Acquir Immune Defic Syndr (2017) 0.75
In reply. Anesthesiology (2013) 0.75
Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. Int J Infect Dis (2012) 0.75
Early detection of HIV infection among Kenyan infants using a reverse transcriptase activity assay. Pediatr Infect Dis J (2012) 0.75
Anesthetic Management of Patients With Inborn Errors of Metabolism. Anesth Analg (2016) 0.75
A case of Pneumocystis pneumonia in an HIV-negative patient. J Infect (2003) 0.75
Computer simulation of pathogen transmission in the medical intensive care unit: a comparison of two probabilistic methods. Stud Health Technol Inform (2004) 0.75
Optimal Anti-Retroviral Prophylaxis in Infants At High-Risk of Acquiring Human Immunodeficiency Virus: A Systematic Review. Pediatr Infect Dis J (2017) 0.75
Translating Technical Support Into Country Action: The Role of the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers, and Children in the Global Plan Era. J Acquir Immune Defic Syndr (2017) 0.75
Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr (2017) 0.75
Anesthetic considerations in Netherton Syndrome. Paediatr Anaesth (2012) 0.75
Pediatric Treatment Scale-Up: The Unfinished Agenda of the Global Plan. J Acquir Immune Defic Syndr (2017) 0.75
Anesthetic considerations in Sheldon-Hall syndrome. Paediatr Anaesth (2014) 0.75